Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-175,000
Closed -$11.6M 42
2025
Q4
$11.6M Buy
+175,000
New +$11.3M 0.72% 22
2016
Q3
Sell
-60,000
Closed -$1.19M 28
2016
Q2
$1.19M Sell
60,000
-100,000
-63% -$1.7M 1.18% 24
2016
Q1
$2.72M Buy
160,000
+92,000
+135% +$1.54M 3.12% 15
2015
Q4
$1.39M Buy
+68,000
New +$1.41M 1.23% 22

Other funds holding DXCM

Casdin Capital's DXCM Position: Q1 2026 in Review

Casdin Capital sold out of DexCom (DXCM) in Q1 2026, closing a stake of 175,000 shares — an estimated $11.6M sold.

Casdin Capital first reported a position in DXCM in Q4 2015 and held it in 4 quarters. The position peaked at $11.6M in Q4 2025. 957 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • Casdin Capital reported no remaining DexCom position as of Q1 2026 after selling out during the quarter.
  • Casdin Capital sold 175,000 DexCom shares in Q1 2026, an estimated $11.6M.
  • Casdin Capital first reported a position in DexCom in Q4 2015 and held it in 4 quarters.
  • Casdin Capital's DexCom position peaked at $11.6M in Q4 2025.
  • 957 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Casdin Capital's 13F filing for Q1 2026, filed 15 May 2026.